Welcome!

Innovative Approaches to Optimal Cancer Care in Canada
April 7 – 8, 2017

Innovative Approaches to Optimal Cancer Care in Canada is a one-of-a-kind opportunity to connect with cancer colleagues from across Canada and learn about innovations in cancer care.

Join us and hear from renowned international and Canadian speakers who will inspire you with insights that span the cancer care continuum – screening, diagnosis and treatment, palliative and end-of-life care, and survivorship – and delve into key themes:

  • Quality of care for all
  • Diagnostic process: A clear pathway or a revolving door?
  • Overcoming inertia in the cancer system: Why don’t we do what we know works?

Who should attend? Health-care practitioners, leaders and key stakeholders who want to connect with colleagues and be part of important conversations that are changing the cancer experience in Canada:

  • What are the most promising advances in cancer care today?
  • How can we accelerate their adoption for the benefit of Canadian patients?
  • How can we improve cancer care for patients through system-level change?

The conference is CME accredited, allowing clinicians to earn credits toward their continuing medical education.

We look forward to welcoming you to Toronto on April 7-8, 2017.

Registration & Hotel

Registration

Online registration is now open for the Innovative Approaches to Optimal Cancer Care in Canada conference. To register for the conference please visit our event registration website.

  • Before February 17, 2017: $275
  • After February 17, 2017: $350

Note: All fees are shown in Canadian funds and not inclusive of tax.

Hotel

The conference will be held at the Westin Harbour Castle in Toronto, Ontario.

If you require accommodation, we have negotiated a preferred hotel rate ($199 single/$219 double) at the Westin Harbour Castle. Visit the hotel’s website to reserve online or call 1-888-627-8558.

Reserve by March 6, 2017 and note that you are attending the Innovative Approaches to Optimal Cancer Care in Canada conference to take advantage of the preferred rate.

Visit the Westin Harbour Castle website for details on how to travel to the hotel upon arriving in Toronto.

Travel

Air Canada is offering a 10% discount for non-Tango fares for flights booked through aircanada.com. Enter promotion code CW8X7EX1 in the search panel.

Abstracts

The abstract submission deadline for the conference has passed. Please visit the abstract website for more details.

The Scientific Program Committee reviewed high-quality abstracts.

Abstracts were considered for the following categories:

  • Specific, replicable initiatives to improve the quality of cancer care
  • Improving the diagnostic process
  • Cost and sustainability
  • Implementation science focused on demonstrated improvements in cancer services

Program & Speakers

Program

Join us and hear from renowned international and Canadian speakers who will inspire you with insights that span the cancer care continuum and delve into key themes:

  • Quality of care for all
  • Diagnostic process: A clear pathway or a revolving door?
  • Overcoming inertia in the cancer system: Why don’t we do what we know works?

Preliminary scientific program

Below is an outline of the preliminary scientific program. Please visit the abstract website for more details.

The conference is CME accredited, allowing clinicians to earn credits toward their continuing medical education.


Day One: April 7, 2017

7:00 AM – 8:00 AM Registration/Breakfast
8:00 AM – 8:45 AM Opening remarks and setting the stage

 

Theme 1: Quality Initiatives

Chair: Dr. Geoff Porter, Expert Lead, Clinical Care

In this session, you will:

  • Learn about the principles and challenges of cancer quality improvement initiatives internationally
  • Through examples, gain insights on modality specific approaches to quality improvements in cancer care
8:45 AM – 8:55 AM A Patient Story

Mike Lang, Medical Humanities Researcher, University of Calgary; Senior Consultant, Alberta Health Services

  • Use of patient storytelling in cancer
8:55 AM – 9:55 AM

 

International experiences: Principles and challenges of cancer quality improvement initiatives

  • The UK Perspective – Dr. Chris Harrison, National Clinical Director for Cancer, NHS England
  • The US Perspective – Dr. Eric Schneider, Senior Vice President for Policy and Research, The Commonwealth Fund
9:55 AM – 10:45 AM

 

 

Canadian experiences of quality initiatives:

  • Canadian Partnership for Quality Radiotherapy – Dr. Mike Milosevic, Director of Research and Quality, Radiation Medicine Program, Princess Margaret Cancer Centre and University Health Network
  • Cancer systematic therapy quality initiatives – Dr. Monika Krzyzanowska, Medical Oncologist and Health Services Researcher, Princess Margaret Cancer Centre
  • Colorectal cancer quality improvement initiatives – Dr. Marko Simunovic, Professor of Surgery, McMaster University and Juravinski Cancer Centre
  • Bladder cancer surgery and quality challenges – Dr. Armen Aprikian, Chief of Urology, McGill University Health Centre

Panel Discussion and Q&A

10:45 AM – 11:00 AM Break/Poster Viewing
11:00 AM – 12:00 PM Concurrent sessions: CS1 – CS5

CS1: Cost and sustainability
Chair: Carole Chambers, Director, Cancer Services, Alberta Health Services Pharmacy

  • Cost-effectiveness of smoking cessation within an organized CT lung cancer screening program: Implications for clinical intervention opportunities (William Evans)
  • Over 75% of thyroid cancer in Canada is overdiagnosed and over-treated (James Dickinson)
  • Impacts of American Society Clinical Oncology (ASCO) versus Canadian Task Force on Preventive Health Care (CTFPHC) guidelines for cervical cancer screening (Catherine Popadiuk and Cindy Gauvreau)
  • Laparoscopic versus open gastrectomy for gastric cancer patients: A population-based cost analysis (Yunni Jeong)
  • Are value frameworks useful in helping Canadian cancer systems determine funding for new therapies? (Barry D. Stein, Carole Chambers, Alexandra Chambers and Newell McElwee)
  • What is the value of Cancer Care Ontario’s Breast Cancer Well Follow-up Care Initiative? (Nicole Mittmann)

CS2: Implementation science focused on demonstrated improvement in cancer services
Chair: Dr. Robyn Tamblyn, Scientific Director, Institute of Health Services and Policy Research, Canadian Institutes of Health Research

  • Implementation of a train-the-trainer curriculum to enhance palliative care for children with cancer (Kimberley Widger)
  • Palliative Radiotherapy Integrated Symptom Management (PRISM): Robust cross-bridging towards patient-centred care (Fleur Huang)
  • Improving the quality of cancer care: pan-Canadian study results on transitions following treatment (Susana Huang)
  • Improving outcomes for cancer patients presenting to Emergency Department (ED) with Febrile Neutropenia (Kardi Kennedy and Tara Baetz)
  • The use of administrative data to inform cancer policy initiatives: Integrating administrative data to track the cancer patient’s journey (Oliver Bucher)
  • Reduced wait-times to colonoscopy after positive Guaiac Fecal Occult Blood Test (gFOBT) in Ontario’s Diagnostic Assessment Programs (DAPs) compared to usual care (Nathaniel Jembere and Jill Tinmouth)

CS3: Improving the diagnostic process
Chair Dr. David Mowat, Senior Scientific Leader, Population Health, Canadian Partnership Against Cancer

  • Effect of screening test choice on colorectal cancer (CRC) risk and colonoscopy use (Andrew J. Coldman)
  • The breast cancer diagnostic interval across five Canadian provinces: A CanIMPACT study (Patti A. Groome)
  • Post-colonoscopy colorectal cancers: A step towards identification of root causes and potential points of intervention (Clarence K. Wong)
  • An analysis of FIT results and neoplastic findings from the Newfoundland and Labrador Colon Cancer Screening Program (Jerry S. McGrath)
  • Timeliness of referrals using a radiology-initiated notification process for patients suspected of having lung cancer (Ashley-Mae Gillson and James Veenstra)
  • The benefits and harms of breast cancer screening: Time trends for four key indicators (Jennifer Payne and Gregory Doyle)

CS4: Specific replicable initiatives on improving quality of cancer care, Part I
Chair: Dr. Mike Milosevic, Director of Research and Quality, Radiation Medicine Program, Princess Margaret Cancer Centre and University Health Network

  • Why does Calgary have one of the lowest hospital death rates for cancer patients in Canada? Perspectives from a large integrated, palliative care program (Aynharan Sinnarajah)
  • Using patient reported outcome measure for personalized cancer care: Impact on patient activation and health care utilization (Doris Howell and Nicole Montgomery)
  • early integration of palliative care in Ontario in cancer settings: INTEGRATE Quality Improvement Project (Marnie MacKinnon)
  • Improving screening mammography return rates in overdue women: A recall initiative using signed family physician letters (Janette Sam)
  • Paramedics Providing Palliative Care at Home Program in Nova Scotia and Prince Edward Island, Canada (Marianne Arab)
  • Radiologist one-year recall recommendation rate after a normal breast screen: Implementing provider practice change by performance monitoring and intervention (Derek Muradali)

 

CS5: Specific replicable initiatives on improving quality of cancer care, Part II
Chair: Dr. Deb Dudgeon, Senior Scientific Leader, Person-Centred Perspective, Canadian Partnership Against Cancer

  • ‘Swing Rooms’ – an innovative resource utilization model to improve combined care and access to immediate breast reconstruction (Esta S. Bovill)
  • Adherence to guidelines for breast cancer survivor care across five Canadian provinces: A CanIMPACT study (Mary L. McBride)
  • International collaboration in the introduction of transanal total mesorectal excision (TaTME) in a Canadian high volume rectal cancer surgical centre (Carl Brown)
  • A pan-Canadian project to rapidly disseminate radiation oncology peer review as a quality improvement initiative: A mixed-method evaluation (Michael Brundage)
  • Observations on variation in cancer surgery in Canada from prospective data collected at point of care with a synoptic reporting tool (Iresha Ratnayake, Andrea Hilchie-Pye, Lorilee Scott and Lloyd Mack)
  • Radiotherapy (RT) utilization: A knowledge translation program to ensure that all Ontarians who need RT receive it (Michael Brundage)
12:00 PM – 12:45 PM Lunch/Poster Viewing

 

Theme 2: Economics of High Quality Care

Chair: Dr. Terry Sullivan, Expert Lead, Quality Initiatives, Canadian Partnership Against Cancer

In this session, you will:

  • Gather insights about promises and limits of tracking real-world evidence of cancer treatment
  • Understand clinical and organizational perspectives on cancer cost management, control, purchase, evaluation and gaps
  • Learn about Canadian cancer costing initiatives
  • Identify and discuss implications of cost on clinical decision-making and potential impact on patient outcomes
12:45 PM – 12:55 PM A Patient Story

Mike Lang, Medical Humanities Researcher, University of Calgary; Senior Consultant, Alberta Health Services 

12:55 PM – 2:20 PM

 

Impact of economics on the cancer system: Perspectives on quality, cost and impact on outcomes

  • Using a framework to guide the decision-making process to address Canadian challenges related to cancer treatment demand and expenditure – Dr. Stuart Peacock, Co-Director, Canadian Centre for Applied Research in Cancer Control
  • Real-world evidence in cancer chemotherapy from the UK – Dr. Michael Wallington, Senior Public Health Intelligence Analyst, National Cancer Registration and Analysis Service, Public Health England
  • The increasing cost of chemotherapy – Dr. Claire de Oliveira, Expert Lead, Cancer Economics, Canadian Partnership Against Cancer
  • Influencing clinical service design by integrating current Canadian costing models – Dr. Tallal Younis, Professor of Medicine and Clinician Investigator, Queen Elizabeth II Health Sciences Centre
  • Negotiating, purchasing, evaluating and identifying gaps in cancer drugs – Suzanne McGurn, Assistant Deputy Minister and Executive Officer of Ontario’s Public Drug Programs

Panel Discussion and Q&A

2:20 PM – 2:35 PM Break/Poster Viewing

 

Theme 3: Improving the quality of cancer diagnosis

Chair: Dr. Christian Finley, Expert Lead, Clinical Measures, Canadian Partnership Against Cancer

In this session, you will:

  • Reflect on and discuss expanding the role of primary care in cancer diagnosis using the UK as an example
  • Review Canadian data to gain insight into the current and future role of primary care in cancer diagnosis
  • Learn from Canadian examples of innovations in cancer diagnostic process and reflect on what can be applied in practice
2:35 PM – 2:45 PM A Patient Story:

Mike Lang, Medical Humanities Researcher, University of Calgary; Senior Consultant, Alberta Health Services

2:45 PM – 3:55 PM

 

Expanding the role of primary care in cancer control

  • The organization of services, including physicians, in cancer diagnosis (Canadian Perspective) – Dr. Eric Wasylenko, Medical Director, Health System Ethics and Policy, Health Quality Council of Alberta
  • Pathways, diagnostic testing and role of primary care (International Perspective) – Dr. Greg Rubin, Professor of General Practice and Primary Care, Durham University (UK)
  • Primary care in cancer diagnosis (Canadian Perspective) – Dr. Eva Grunfeld, Chair, Chronic Conditions Institute Advisory Board for Canadian Institutes for Health Research

Panel Discussion and Q&A

3:55 PM – 5:05 PM Cancer diagnosis: Quality initiatives and innovations

  • Technologies absorbed/ integrated in the pathway – Dr. Stirling Bryan, Director, Centre for Clinical Epidemiology & Evaluation
  • Canadian pathology quality initiatives and innovations – Dr. John Srigley, Expert Lead, Pathology, Canadian Partnership Against Cancer
  • Thoracic oncology program – Nadine Strilchuk, Nurse Practitioner, Thoracic Oncology Program, Alberta Health Services
5:05 PM – 5:10 PM Closing remarks: Setting the stage for Day Two

  • Dr. Craig Earle, Program Director, Health Services Research, Ontario Institute for Cancer Research
5:10 PM – 6:00 PM Reception/Poster Viewing

 

Day Two: April 8, 2017

Theme 4: Overcoming inertia in the cancer system: Why don’t we do what we know works?

Chair: Dr. Craig Earle, Program Director, Health Services Research, Ontario Institute for Cancer Research

In this session, you will:

  • Learn key principles addressing the challenges to implementation of known effective cancer innovations
  • Discuss and refine ideas regarding the implementation of specific initiatives that  could be done now to improve the quality of cancer care
8:30 AM – 9:15 AM Why we are not applying what we know?

  • Dr. David Currow, Chief Cancer Officer, New South Wales
9:15 AM – 10:00 AM Formal reactions

  • Dr. Malcolm Moore, President, BC Cancer Agency
  • Dr. Mary Gospodarowicz, Medical Director, Princess Margaret Cancer Centre
  • Dr. Geoff Porter, Expert Lead, Clinical Care, Canadian Partnership Against Cancer
10:00 AM – 10:20 AM Break/Networking
10:20 AM – 11:10 AM What are five things we could do immediately to improve cancer care in Canada?

  • Dr. Craig Earle, Program Director, Health Services Research, Ontario Institute for Cancer Research

Panel discussion

  • Dr. Malcolm Moore, President, BC Cancer Agency
  • Dr. Ari Meguerditchian, Staff Surgical Oncologist and Health Services Researcher, McGill University
  • Dr. Michael Sherar, President and CEO, Cancer Care Ontario
  • Dr. Adalsteinn Brown, Director, Institute of Health Policy, Management and Evaluation, University of Toronto
11:10 AM – 11:15 AM A Patient Story:

Mike Lang, Medical Humanities Researcher, University of Calgary; Senior Consultant, Alberta Health Services

11:15 AM  -11:30 PM What we heard: Now for the future

  • Dr. Heather Bryant, Vice President, Cancer Control, Canadian Partnership Against Cancer
11:30 AM – 12:30 PM Formal poster viewing session with poster presenters/Box lunch

Speakers

International keynote speakers include:

Eric Schneider
Picture of Eric Schneider
X

Eric Schneider

United States: Principles and challenges of quality improvement initiatives

Dr. Eric Schneider is senior vice president for policy and research at The Commonwealth Fund, a private foundation that supports independent research on health policy around the globe. Dr. Schneider’s research has focused on evaluating and improving the quality and safety of health care.

Prior to joining the Fund, Dr. Schneider held the RAND Distinguished Chair in Health Care Quality.  In 2009, he became the first director of RAND’s Boston office. From 1997 to 2014, he was faculty of Harvard Medical School and Harvard School of Public Health where he taught health policy and quality improvement in health care and practiced primary care internal medicine at Brigham and Women’s Hospital in Boston.

Dr. Schneider holds a B.S., cum laude, in Biology from Columbia University, an M.Sc. from the University of California, Berkeley, and an M.D. from the University of California, San Francisco. He is an elected fellow of the American College of Physicians.

Greg Rubin
Picture of Greg Rubin
X

Greg Rubin

United Kingdom: Streamlining the early diagnostic process

Dr. Greg Rubin is Professor of General Practice and Primary Care at Durham University, UK and directs their Evaluation, Research and Development Unit.

With over 190 peer-reviewed publications, book chapters and reports, his current research focuses on the diagnosis and management of cancer in primary care and at the interface with secondary care.

He leads a substantial program of externally-funded research and service development in this field and is a senior investigator in the Department of Health-funded Policy Research Unit for Cancer Awareness, Screening and Early Diagnosis.

He advises Government and Cancer Research UK on the implementation of cancer strategy, was the Royal College of General Practitioners’ Clinical Lead for Cancer until 2014 and led the first English audit of cancer diagnosis in primary care.

David Currow
Picture of David Currow
X

David Currow

Australia: Why are we not applying what we know?

Dr. David Currow is the Chief Cancer Officer, NSW and Chief Executive Officer, Cancer Institute NSW, the NSW Government’s cancer control agency.  The role of the Cancer Institute NSW is to decrease the incidence of cancer, increase survival for cancer patients and improve the quality of care for people with cancer.

He leads a team of 200 people whose expertise and scope of activities include prevention (tobacco control, ultraviolet light protection), screening (BreastScreen, Cervical Screening and Bowel Screening), service performance and development (including Australia’s sole population-based clinical cancer registry), eviQ – the world’s major evidence-based protocol website in oncology, and Canrefer (linking general practitioners and consumers with multidisciplinary teams), and strategic research and investment.

Prior to joining the Institute in 2010, he was the foundation CEO of Cancer Australia, the Commonwealth’s cancer control agency.

  • Chris Harrison, National Clinical Director for Cancer, NHS England
  • Michael Wallington, Senior Public Health Intelligence Analyst, National Cancer Registration and Analysis Service, Public Health England

Canadian thought leaders include:

Heather Bryant
Picture of Heather Bryant
X

Heather Bryant

Vice-President, Cancer Control

Heather Bryant, MD, PhD, CCFP, FRCPC, joined the Partnership in January 2008 from the Alberta Cancer Board, where she was Vice-President and Chief Information Officer and Director of the Division of Population Health and Information.

At the Alberta Cancer Board, she was responsible for the cancer registry, screening and prevention programs, as well as an active research unit in cancer epidemiology and prevention. In addition, she led electronic health record implementation.

Dr. Bryant studied medicine at the University of Calgary and took her first residency certification in family medicine. She followed this with a fellowship in community medicine and a PhD in epidemiology, also at the University of Calgary. Dr. Bryant joined the Alberta Cancer Board in 1990. Before that she was a faculty member at the University of Calgary while also a Medical Officer of Health in the Drumheller Health Unit.

Dr. Bryant was elected to the Union for International Cancer Control (UICC) Board of Directors in 2012 and was re-elected in 2014. She co-chaired the scientific program committee for UICC’s World Cancer Congress held in Montreal, Quebec in 2012 and in Melbourne, Australia in 2014.

Dr. Bryant has also been active on many national committees and chaired the National Committee for the Canadian Breast Cancer Screening Initiative (Health Canada), the Joint Advisory Committee on Cancer Control (National Cancer Institute of Canada) and the Population Health Committee (Medical Research Council). She was the inaugural chair of the Institute of Cancer Research’s Advisory Board (Canadian Institutes for Health Research) and of the National Colorectal Cancer Screening Network. Dr. Bryant is also a Clinical Professor in the departments of Community Health Sciences and Oncology at the University of Calgary.

Claire de Oliveira, PhD
Picture of Claire de Oliveira, PhD
X

Claire de Oliveira, PhD

Expert Lead, Cancer Economics

Dr. Claire de Oliveira joined the Canadian Partnership Against Cancer as Expert Lead, Cancer Economics in 2016. In this role, she develops health economics expertise within the Partnership and supports efforts to deepen the capacity to quantify the burden of cancer and assess the economic impact of a coordinated, pan-Canadian approach to cancer control. She also works across cancer control initiatives to quantify efficiencies and support efforts to improve the sustainability of the cancer control system. Dr. de Oliveira is also a member of the Partnership’s Analytic Capacity Building Committee.

Dr. de Oliveira is a health economist at the Centre for Addiction and Mental Health; an assistant professor at the Institute of Health Policy, Management and Evaluation at the University of Toronto; and an adjunct scientist at the Institute for Clinical Evaluative Sciences. Her main areas of cancer-related research include the development of costing methodology, the use of administrative health care data to measure health services utilization and costs, and the assessment of value for money in cancer care.

Dr. de Oliveira holds membership with the Canadian Centre for Applied Research in Cancer Control and is one of the program leads for Health Technology Assessment. In addition, she is a collaborator at the Toronto Health Economics Technology Assessment Collaborative.

Dr. de Oliveira holds Masters of Arts and Doctorate degrees in economics from McMaster University. She also holds a licentiate degree in economics from the University of Oporto in Portugal.

Craig Earle
Picture of Craig Earle
X

Craig Earle

Dr. Craig Earle, Program Director, Health Services Research, Ontario Institute for Cancer Research

Dr. Craig Earle is a Medical Oncologist at Sunnybrook’s Odette Cancer Centre in Toronto, the Director of the Ontario Institute for Cancer Research’s Health Services Research and Clinical Trials Programs, a Senior Scientist and the Cancer Program Leader at the Institute for Clinical Evaluative Sciences, and a Professor of Medicine at the University of Toronto.

Dr. Earle is currently the Chair of the Ontario Steering Committee for Cancer Drug Programs, a member of the pan-Canadian Oncology Drug Review Expert Review Committee, and a Co-Chair of the Ontario Cancer System Quality Index Project Leadership Team.

Dr. Earle’s personal research interests focus on evaluating and improving the quality of care received by patients with advanced cancer and cancer survivors, the effect of financial incentives on care delivery, and making linked, de-identified administrative data more available for health research.

Geoff Porter, MD
Picture of Geoff Porter, MD
X

Geoff Porter, MD

Expert Lead, Clinical Care

Dr. Geoff Porter is Expert Lead, Clinical Care. He previously served as the Partnership’s inaugural Senior Scientific Leader, Diagnosis and Clinical Care.

Serving in his Partnership role on a part-time basis, Dr. Porter is a Professor of Surgery and the Ramia Chair in Surgical Oncology at Dalhousie University. He also serves as Director of the Cancer Outcomes Research Unit in Halifax, where he has worked to generate standard research metrics in the forms of publications and grants, as well as significant knowledge translation and exchange activities, resulting in tangible clinical change. In the past, he has served as the Head of the Cancer Care Program in Halifax, as well as the Chair of Surgical Quality Control for the Radiation Therapy Oncology Group (RTOG).

Dr. Porter studied medicine at Queen’s University in Kingston, Ontario and also holds a Master of Science in medical sciences, specializing in epidemiology, from the University of Alberta. He trained in Surgical Oncology at the MD Anderson Cancer Center in Houston, Texas.

Over the past several years, Dr. Porter has participated in several Partnership initiatives, working groups, steering committees and reports, notably as Clinical Lead for breast cancer surgery in the Synoptic Reporting Tools Project. In addition, he acted as Chair of the Electronic Synoptic Surgery Quality Initiative which has led to the doubling of surgeons using synoptic reporting tools with a focus on using the results to further cancer control. He also led the Partnership’s submission for the Choosing Wisely Canada oncology list of recommendations to identify low-value or potentially harmful practices, contributing to landmark recommendations for the cancer control community.

John Srigley, MD
Picture of John Srigley, MD
X

John Srigley, MD

Expert Lead, Pathology

Dr. Srigley is the Chief and Medical Director of the Program of Laboratory Medicine and Genetics at Trillium Health Partners, and a Professor in the Department of Pathology and Molecular Medicine at McMaster University. He also represents Canada on the American Joint Committee on Cancer. In addition to his role as Expert Lead, Pathology, Dr. Srigley is Chair of the National Pathology Standards Committee at the Canadian Partnership Against Cancer.

Dr. Srigley is a graduate of the Faculty of Medicine, University of Toronto, where he also received pathological training, which he continued at MD Anderson Cancer Centre in Houston.

Previously, Dr. Srigley was the inaugural Head of Pathology and Laboratory Medicine Program at Cancer Care Ontario. Dr. Srigley is a Past President of both the International Society of Urological Pathologists and the Ontario Association of Pathologists. Dr. Srigley was a key leader in completing the Partnership’s National Staging Initiative and securing formal endorsement of the College of American Pathology cancer checklists as pan-Canadian content standards for cancer pathology reporting. An international consultant and educator in the fields of oncologic and urologic pathology, Dr. Srigley has contributed extensively to the literature and strongly advocated for population-level standardized synoptic pathology reporting and the role of the pathologist in cancer control.

Tallal Younis
Picture of Tallal Younis
X

Tallal Younis

Dr. Tallal Younis, Clinician Investigator, Queen Elizabeth II Health Sciences Centre

Dr. Tallal Younis is a Professor of Medicine at Dalhousie University and a Clinician Investigator at the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia. His academic practice is focused on breast cancer and he is a co-chair of the provincial multidisciplinary breast site team.

Dr. Younis is a member of the Canadian Partnership Against Cancer’s (the Partnership) Diagnosis and Clinical Care Advisory Group and an editor for the medical oncology section of Current Oncology. He is past member of the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) as well as the Partnership’s Research Advisory Group

Dr. Younis’ research interests involve health services research and health technology assessments in breast cancer. He has received funding from a number of granting agencies including the Canadian Institutes for Health Research (CIHR), the Canadian Breast Cancer Foundation and the Breast Cancer Society of Canada. He has authored and/or co-authored more than a 100 publication and abstracts primarily in the field of health economics research in breast cancer.

Dr. Younis received his medical degree from Cairo University in 1992 and a degree from MRCPUK (Membership of the Royal Colleges of Physicians of the United Kingdom) in 1998. He completed an internal medicine residency in 2001 at Columbia University in New York and a Medical Oncology Fellowship in 2003 at the Roswell Park Cancer Institute in Buffalo. He is board certified (ABIM) in Internal Medicine and Medical Oncology.

  • Armen Aprikian, Chief of Urology, McGill University Health Centre
  • Adalsteinn Brown, Director, Institute of Health Policy, Management and Evaluation, University of Toronto
  • Stirling Bryan, Director, Centre for Clinical Epidemiology & Evaluation
  • Heather Bryant, Vice President, Cancer Control, Canadian Partnership Against Cancer
  • Mary Gospodarowicz, Medical Director, Princess Margaret Cancer Centre
  • Eva Grunfeld, Chair, Chronic Conditions Institute Advisory Board for Canadian Institutes for Health Research
  • Ari Meguerditchian, Staff Surgical Oncologist and Health Services Researcher, McGill University
  • Mike Milosevic, Director of Research and Quality, Radiation Medicine Program, Princess Margaret Cancer Centre and University Health Network
  • Monika Krzyzanowska, Medical Oncologist and Health Services Researcher, Princess Margaret Cancer Centre
  • Suzanne McGurn, Assistant Deputy Minister and Executive Officer of Ontario’s Public Drug Programs
  • Malcolm Moore, President, BC Cancer Agency
  • Michael Sherar, President and CEO, Cancer Care Ontario
  • Marko Simunovic, Professor of Surgery, McMaster University and Juravinski Cancer Centre
  • Nadine Strilchuk, Nurse Practitioner, Thoracic Oncology Program, Alberta Health Services
  • Stuart Peacock, Co-Director, Canadian Centre for Applied Research in Cancer Control
  • Eric Wasylenko, Medical Director, Health System Ethics and Policy, Health Quality Council of Alberta

Contact

If you have questions about the Innovative Approaches to Optimal Cancer Care in Canada conference please contact: cancerconf@partnershipagainstcancer.ca